Internal Medicine, Gastroenterology · Mesa, AZ
NPI
1538264684
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
3048 E Baseline Rd, Suite 105
Mesa, AZ, 85204
Phone (480) 545-6060
Groups this clinician bills Medicare through
Medicare paid, 2024
$93K
929 services
Medicare patients, 2024
594
Average age 73
Drug cost, 2024
$696K
1,390 prescriptions
Company payments, 2025
$7,822
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Elisa M Faybush was code 99213 (office e&m - established), 180 times for 163 patients. In total Elisa M Faybush billed 929 services in 32 codes, and Medicare paid $93K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-02-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 180 | 163 | $61.40 | $11K |
| 45385 Colonoscopy - Lesion Removal | Facility | 134 | 134 | $199.56 | $27K |
| 99203 Office E&M - New | Office | 109 | 109 | $72.38 | $7,890 |
| 43239 Upper GI Endoscopy | Facility | 94 | 93 | $74.44 | $6,997 |
| 45380 Lower GI Endoscopy - Other | Facility | 73 | 73 | $102.37 | $7,473 |
| 99214 Office E&M - Established | Office | 44 | 42 | $73.78 | $3,246 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 42 | 42 | $171.80 | $7,215 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 39 | 39 | $169.57 | $6,613 |
| 99204 Office E&M - New | Office | 39 | 39 | $96.56 | $3,766 |
| 43249 Upper GI Endoscopy | Facility | 36 | 34 | $91.26 | $3,286 |
| 99212 Office E&M - Established | Office | 11 | 11 | $39.50 | $435 |
By year: 2022 $103K for 1,078 services; 2023 $98K for 1,297 services; 2024 $93K for 929 services.
Medicare prescription drug claims, 2024
In 2024, the drug Elisa M Faybush prescribed most often to Medicare patients was Omeprazole, with 226 prescriptions and refills. In total Elisa M Faybush wrote 1,390 Medicare prescriptions that cost $696K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Omeprazole Generic | 226 | 575 | 91 | $3,308 |
| Pantoprazole Sodium Generic | 195 | 547 | 78 | $3,697 |
| Famotidine Generic | 142 | 400 | 78 | $1,745 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 93 | 93 | 93 | $6,162 |
| Budesonide Dr Budesonide | 39 | 61 | 12 | $3,945 |
| Colestipol Hcl Generic | 37 | 62 | 19 | $3,529 |
| Linzess Linaclotide | 35 | 73 | 17 | $38K |
| Diphenhydramine Hcl Generic | 33 | 33 | Under 11 | $765 |
| Nortriptyline Hcl Generic | 32 | 52 | Under 11 | $270 |
| Clenpiq Sod Picosulf/Mag Ox/Citric Ac | 31 | 31 | 31 | $5,467 |
| Sucralfate Generic | 29 | 29 | Under 11 | $3,173 |
| Creon Lipase/Protease/Amylase | 28 | 36 | Under 11 | $102K |
| Mesalamine Generic | 27 | 57 | Under 11 | $18K |
| Dicyclomine Hcl Generic | 27 | 48 | 13 | $733 |
| Ondansetron Hcl Ondansetron Hcl/Pf | 25 | 25 | Under 11 | $152 |
Brand drugs: 268 claims; generic drugs: 1,122 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Elisa M Faybush $7,822 ($7,822 in general payments such as food, travel and fees) from 23 companies. The largest payer was Exact Sciences Corporation with $4,978.
| Company | Payments | Amount |
|---|---|---|
| Exact Sciences Corporation EXAS | 11 | $4,978 |
| Abbvie Inc. ABBV | 31 | $749 |
| QOL Medical, LLC | 9 | $265 |
| Pfizer Inc. PFE | 18 | $232 |
| Janssen Biotech, Inc. JNJ | 11 | $224 |
| Madrigal Pharmaceuticals MDGL | 7 | $184 |
| Lilly USA, LLC LLY | 8 | $148 |
| Novo Nordisk Inc NVO | 2 | $141 |
| Phathom Pharmaceuticals, Inc. PHAT | 13 | $140 |
| Celltrion USA Inc. 068270.KS | 8 | $137 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.